Open
Actively Recruiting
Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer
About
Brief Summary
This clinical trial tests the the feasibility of testing a red blood cell transfusion threshold for improved quality of life for patients undergoing a pancreatectomy for pancreatic cancer. Pancreatectomy can be associated with significant blood loss. Blood loss can result in clinically important anemia causing fatigue. Pancreatic cancer itself can be associated with malnutrition and fatigue. Having a red blood cell transfusion threshold that results in a more liberal use of transfusions may improve quality of life for patients undergoing a pancreatectomy for pancreatic cancer.
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Male or female >= 18 years of age at Visit 1
- Documentation of a pancreatic cancer diagnosis as evidenced by one or more clinical features meeting the following criteria:
- CT evidence of a mass in the pancreas consistent with cancer
- Tissue diagnosis of cancer either before surgery or from the resected specimen
- Preoperative evaluation suggestive that pancreatic resection is feasible
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study
Exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
- Patients who are unable to receive or who refuse blood products
- Patients involved in an autologous pre-donation program
- Patients found to have metastatic disease upon entry into abdomen-having been randomized, these patients will be removed from the study and replaced with another patient
- Patients found to not have cancer during the operation- If the resected lesion proves not to be cancer, the patient will remain as an enrolled patient but not evaluable and replaced by another patient
- Established severe cardiovascular disease with estimated 5-year survival <10% based on Framingham risk score
- Unstable angina or recent myocardial infarction (MI)/stroke within 6 months
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
22-001796
Category
Pancreatic Cancer
Principal Investigator
Contact
Location
- UCLA Westwood